SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

SKYE

Skye Bioscience, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The strong clinical data supports potential differentiation for nimacimab in combination with incretin therapies, but the significant increase in cash burn raises concerns about future dilution risk. Traders should monitor Q4 2026 topline data from the higher-dose expansion study and finalization of the Phase 2b protocol as key catalysts.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.7210
T+0 close · Mar 10, 2026 · via day close
Latest settled
+6.80%
T+60 · $0.7700
Vs SPY
−4.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $0.7210entry
  2. T+1 · 8mo ago −1.94%α −0.46% · $0.7070
  3. T+5 · 8mo ago −6.66%α −4.47% · $0.6730
  4. T+20 · 7mo ago +0.69%α +0.17% · $0.7260
  5. T+60 · 6mo ago +6.80%α −4.73% · $0.7700
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesity candidate nimacimab, including initiation of a higher-dose expansion study and FDA feedback shaping Phase 2b design. The company emphasized strong combination data with semaglutide, showing 22.3% mean weight loss at 52 weeks and favorable body composition outcomes, but reported a significant net loss increase due to higher R&D and manufacturing costs. Cash runway is expected through Q4 2026, excluding Phase 2b clinical costs.

Key Financial Metrics

EPS
$-1.41

Key Facts

  • Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts to assess safety and pharmacokinetics; topline data expected Q4 2026.
  • Received FDA Type C meeting feedback informing Phase 2b combination trial design with incretin therapy.
  • Interim 52-week data: 22.3% weight loss with nimacimab + semaglutide, no plateau observed, strong safety profile maintained.
  • 13-week off-treatment follow-up: combination cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone; maintained fat loss and gained lean mass.
  • Q4 2025 R&D expenses: $11.5M (up from $7.8M in Q4 2024); full-year R&D: $42.4M (vs. $18.7M in 2024).
  • Net loss for 2025: $55.9M (vs. $26.6M in 2024), driven by $20.7M increase in contract manufacturing costs.
  • Cash, cash equivalents, and short-term investments: $25.7M as of December 31, 2025; expected to fund operations through Q4 2026, excluding Phase 2b clinical costs.

Financial Impact

Net loss nearly doubled year-over-year to $55.9M, primarily due to $20.7M increase in manufacturing costs for Phase 2a extension and anticipated Phase 2b supply. R&D spending more than doubled from 2024 to 2025.

net lossR&D expensescash runwaydilution risk

Risk Factors

  • High cash burn may necessitate future equity financing, leading to shareholder dilution.
  • Phase 2b trial design and dosing strategy remain undefined; regulatory path could be delayed.
  • Competitive risk from other obesity therapies in development with more advanced clinical data.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253294

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026